Zdravlje expands EU presence with PazoFront® authorization in Bulgaria

10/11/2023
pilula.jpeg

Zdravlje/Frontier Biopharma has received another Marketing Authorisation in the CEE issued by the Bulgarian Drug Agency for PazoFront® 200mg and 400mg, film-coated tablets (INN: pazopanib). PazoFront’s active substance (pazopanib) is a protein kinase inhibitor that works by preventing the activity of proteins involved in the growth and spread of cancer cells.

Pazopanib is indicated for use in adults to treat:
– kidney cancer that is advanced or has spread to other organs.
– certain forms of soft-tissue sarcoma

PazoFront is a generic version of Novartis’ Votrient which is marketed globally. This marks a proud moment for our company as it expands our presence in the EU and in critical, life-saving medicines.


How we can help?

Reach out to us and let’s discuss how we can support your pharmaceutical manufacturing needs.


CONTACT US


Zdravlje Company Data | Terms Of Use | Privacy policy | Personal Data Processing

© 2025 Zdravlje AD Leskovac. All rights reserved.